Stock Events

Bergenbio ASA 

kr0.19
61
+kr0+0.52% Wednesday 15:28

Statistics

Day High
0.21
Day Low
0.19
52W High
5.82
52W Low
0.08
Volume
32,195,167
Avg. Volume
70,486,400
Mkt Cap
613.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
-1.03
-0.91
-0.79
-0.67
Expected EPS
-0.82
Actual EPS
-0.67

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BGBIO.OL. It's not an investment recommendation.

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Show more...
CEO
Mr. Martin Olin
Employees
18
Country
NO
ISIN
NO0010650013
WKN
000A2DPC0

Listings